BRAF and cancer: al and the commonest mutation was a single phosphomimetic substitution in the kinase activation domain (V600E) that led to activation of the MAPK pathway[10] Although BRAF mutations have been identified in a variety of cancers, their highest incidence to the tune of almost 60% is seen in melanomas[10].